Jason Mills

Canaccord Genuity

Image: Jason Mills

Mr. Mills has been a publishing sell-side analyst with coverage of medical devices for over 15 years. His areas of coverage include Cardiovascular, Imaging/Robotics, Ophthalmology and Women's Healthcare. Mr. Mills joined Canaccord Genuity from First Albany Capital where he was managing director and senior medical devices analyst, and he previously served as a vice president and senior med-tech analyst with Thomas Weisel Partners (now part of Stifel), Mr. Mills has earned awards for his stock picking, including the #2 ranked Medical Devices analyst in the The Wall Street Journal's 2011 "Best on the Street" Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts. Mr. Mills holds a BA in Economics from Yale University and Master of Sports Administration from Ohio University.

Recent Quotes

"We believe EW is best positioned in TAVR among the current Big 2."

— Jason Mills, Canaccord Genuity (2/13/13)
more >

"EW's SAPIEN performed better with regard to PVL versus CoreValve."

— Jason Mills, Canaccord Genuity (9/4/12)
more >

"We reiterate our Buy rating for EW and are increasing our target price."

— Jason Mills, Canaccord Genuity (6/24/12)
more >

"We think this is a fantastic start to EW's U.S. TAVI launch."

— Jason Mills, Canaccord Genuity (5/1/12)
more >

"We're looking for EW's transcatheter valve franchise to grow 40–50% over the next two years."

The Life Sciences Report Interview with Jason Mills (4/18/12)
more >

"ISRG remains one of the best, most consistent growth companies in medtech."

— Jason Mills, Canaccord Genuity (4/16/12)
more >

"We believe results will support FDA approval of EW's SAPIEN."

— Jason Mills, Canaccord Genuity (3/26/12)
more >

Due to permission requirements, not all quotes are shown.